Diabetic dyslipidemia and the metabolic syndrome

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 2, Issue 3, 2008, Pages 208-222

  Cefalu, William T ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Drug therapy; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Triglycerides

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; BEZAFIBRATE; CANNABINOID 1 RECEPTOR; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 47649124262     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.04.001     Document Type: Article

References (145)

1. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
2. Wyatt S.B., Winters K.P., and Dubbert P.M. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 331 (2006) 166-174
3. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
4. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352 (2005) 1138-1145
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
6. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl. (1996) S11-20
7. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
8. Sharrett A.R., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
9. Chapman M.J. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111 (2006) 893-908
10. Ginsberg H.N., and Huang L.S. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 7 (2000) 325-331
11. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
12. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
13. Kahn R. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
14. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
15. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
16. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
17. Athyros V.G., Ganotakis E.S., Elisaf M., and Mikhailidis D.P. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 21 (2005) 1157-1159
18. Reynolds K., and He J. Epidemiology of the metabolic syndrome. Am J Med Sci 330 (2005) 273-279
19. Resnick H.E., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26 (2003) 861-867
20. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
21. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
22. Ogden C.L., Flegal K.M., Carroll M.D., and Johnson C.L. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288 (2002) 1728-1732
23. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
24. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
25. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
26. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
27. James P.T., Leach R., Kalamara E., and Shayeghi M. The worldwide obesity epidemic. Obes Res 9 Suppl. 4 (2001) 228S-233S
28. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 Suppl. 5 (1997) S1-85
29. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
30. Bundred P., Kitchiner D., and Buchan I. Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies. BMJ 322 (2001) 326-328
31. Mayor S. Obesity in children in England continues to rise. BMJ 330 (2005) 1044
32. Veugelers P.J., and Fitzgerald A.L. Prevalence of and risk factors for childhood overweight and obesity. CMAJ 173 (2005) 607-613
33. Vivian E.M. Type 2 diabetes in children and adolescents-the next epidemic?. Curr Med Res Opin 22 (2006) 297-306
34. Goodman E., Dolan L.M., Morrison J.A., and Daniels S.R. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation 111 (2005) 1970-1977
35. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350 (2004) 2362-2374
36. Viner R.M., Segal T.Y., Lichtarowicz-Krynska E., and Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 90 (2005) 10-14
37. Kapiotis S., Holzer G., Schaller G., Haumer M., Widhalm H., Weghuber D., et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 26 (2006) 2541-2546
38. Whitaker R.C., Wright J.A., Pepe M.S., Seidel K.D., and Dietz W.H. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 337 (1997) 869-873
39. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
40. Wannamethee S.G., Shaper A.G., Lennon L., and Morris R.W. Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165 (2005) 2644-2650
41. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
42. Almdal T., Scharling H., Jensen J.S., and Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 164 (2004) 1422-1426
43. Koskinen P., Manttari M., Manninen V., Huttunen J.K., Heinonen O.P., and Frick M.H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
44. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102 (2000) 1014-1019
45. Nigam A., Bourassa M.G., Fortier A., Guertin M.C., and Tardif J.C. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 151 (2006) 514-521
46. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
47. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
48. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
49. Wannamethee S.G., Shaper A.G., and Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 59 (2005) 134-139
50. Snell-Bergeon J.K., Hokanson J.E., Kinney G.L., Dabelea D., Ehrlich J., Eckel R.H., et al. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 28 (2004) 1594-1599
51. Cassidy A.E., Bielak L.F., Zhou Y., Sheedy II P.F., Turner S.T., Breen J.F., et al. Progression of subclinical coronary atherosclerosis: does obesity make a difference?. Circulation 111 (2005) 1877-1882
52. Mora S., Yanek L.R., Moy T.F., Fallin M.D., Becker L.C., and Becker D.M. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation 111 (2005) 1871-1876
53. Gregg E.W., Cheng Y.J., Cadwell B.L., Imperatore G., Williams D.E., Flegal K.M., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 293 (2005) 1868-1874
54. Carroll M.D., Lacher D.A., Sorlie P.D., Cleeman J.I., Gordon D.J., Wolz M., et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
55. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care 26 Suppl. 1 (2003) S83-S86
56. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 (2004) 1496-1504
57. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
58. Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
59. Robins S.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events-VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
60. Whitney E.J., Krasuski R.A., Personius B.E., Michalek J.E., Maranian A.M., Kolasa M.W., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
61. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
62. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
63. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97 (1998) 1029-1036
64. Eberly L.E., Stamler J., and Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163 (2003) 1077-1083
65. Abdel-Maksoud M.F., and Hokanson J.E. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2 (2002) 325-333
66. Galeano N.F., Milne R., Marcel Y.L., Walsh M.T., Levy E., Ngu'yen T.D., et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269 (1994) 511-519
67. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94 (1993) 350-356
68. Bjornheden T., Babyi A., Bondjers G., and Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123 (1996) 43-56
69. Anber V., Griffin B.A., McConnell M., Packard C.J., and Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124 (1996) 261-271
70. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 17 (1997) 1114-1120
71. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 70 (1992) 733-737
72. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., and Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
73. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
74. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
75. Girman C.J., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
76. Ballantyne C.M., Stein E.A., Paoletti R., Southworth H., and Blasetto J.W. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 91 (2003) 25C-27C [discussion 28C]
77. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003) 733-749
78. Malmstrom R., Packard C.J., Caslake M., Bedford D., Stewart P., Yki-Jarvinen H., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40 (1997) 454-462
79. Adiels M., Olofsson S.O., Taskinen M.R., and Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 17 (2006) 238-246
80. Gastaldelli A., Miyazaki Y., Pettiti M., Matsuda M., Mahankali S., Santini E., et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 5098-5103
81. Unger R.H., and Zhou Y.T. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50 Suppl. 1 (2001) S118-S121
82. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl. 1 (2007) S4-41
83. Grundy S.M., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
84. Ratner R., Goldberg R., Haffner S., Marcovina S., Orchard T., Fowler S., et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28 (2005) 888-894
85. Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
86. Pyörälä K., et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 (2004) 1735-1740
87. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98 (1998) 2513-2519
88. Keech A., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
89. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Collins R., Beevers G., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
90. Colhoun H.M., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
91. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
92. Knopp R.H., d'Emden M., Smilde J.G., and Pocock S.J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
93. Collins R., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
94. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
95. Ahmed S., Cannon C.P., Murphy S.A., and Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 27 (2006) 2323-2329
96. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
97. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
98. Schwartz G.G., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes-the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
99. Schwartz G.G., Olsson A.G., Szarek M., and Sasiela W.J. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 28 (2005) 2508-2513
100. LaRosa J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
101. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
102. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
103. Keech A., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
104. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21 (1998) 641-648
105. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
106. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284 (2000) 1263-1270
107. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
108. Canner P.L., Furberg C.D., and McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97 (2006) 477-479
109. McCormack P.L., and Keating G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65 (2005) 2719-2740
110. Hotz W. Nicotinic acid and its derivatives: a short survey. Adv Lipid Res 20 (1983) 195-217
111. Grundy S.M., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162 (2002) 1568-1576
112. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
113. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
114. Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283 (2000) 1695-1702
115. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 280-288
116. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
117. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
118. Psaty B.M., and Furberg C.D. Rosiglitazone and cardiovascular risk. N Engl J Med 356 (2007) 2522-2524
119. Home P.D., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
120. Nathan D.M. Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 357 (2007) 64-66
121. Moon Y.S., and Kashyap M.L. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy 24 (2004) 1692-1713
122. Denke M., Pearson T., McBride P., Gazzara R.A., Brady W.E., and Tershakovec A.M. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 3 (2006) 93-102
123. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
124. Durrington P.N., Tuomilehto J., Hamann A., Kallend D., and Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 64 (2004) 137-151
125. Derosa G., Cicero A.E., Bertone G., Piccinni M.N., Ciccarelli L., and Roggeri D.E. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 26 (2004) 1599-1607
126. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Didangelos T.P., Peletidou A., Kleta D., et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 54 (2005) 1065-1074
127. Tsalamandris C., Panagiotopoulos S., Sinha A., Cooper M.E., and Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk 1 (1994) 231-239
128. Gardner S.F., Marx M.A., White L.M., Granberry M.C., Skelton D.R., and Fonseca V.A. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 31 (1997) 677-682
129. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
130. Zhao X.Q., Morse J.S., Dowdy A.A., Heise N., DeAngelis D., Frohlich J., et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93 (2004) 307-312
131. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
132. Pi-Sunyer F.X., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
133. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
134. Van Gaal L.F., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
135. Barter P.J., and Kastelein J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47 (2006) 492-499
136. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
137. Morehouse L.A., Sugarman E.D., Bourassa P.A., Sand T.M., Zimetti F., Gao F., et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48 (2007) 1263-1272
138. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
139. Bisoendial R.J., Hovingh G.K., El Harchaoui K., Levels J.H., Tsimikas S., Pu K., et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25 (2005) e133-134
140. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
141. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (2005) 1085-1088
142. McKenney J.M., Davidson M.H., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48 (2006) 1782-1790
143. Davidson M.H., McKenney J.M., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 48 (2006) 1774-1781
144. Krishna R., Anderson M.S., Bergman A.J., Jin B., Fallon M., Cote J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370 (2007) 1907-1914
145. Barter P.J., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122